Avenue Therapeutics (ATXI) Institutional Ownership $0.70 -0.05 (-6.42%) As of 10/3/2025 12:44 PM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Avenue Therapeutics (NASDAQ:ATXI)CurrentInstitutional OwnershipPercentage17.34%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$109.57KNumber ofInstitutional Sellers(last 12 months)0 Get ATXI Insider Trade Alerts Want to know when executives and insiders are buying or selling Avenue Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ATXI Institutional Buying and Selling by Quarter Avenue Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Boothbay Fund Management LLC41,089$82K0.0%N/A2.004% 10/18/2024Moss Adams Wealth Advisors LLC11,000$27K0.0%N/A1.169% 8/15/2024Armistice Capital LLC75,000$262K0.0%N/A7.970% 1/28/2022National Asset Management Inc.71,338$65K0.0%-20.1%0.376% 11/16/2021National Asset Management Inc.89,237$133K0.0%-29.2%0.531% 10/19/2021Kestra Advisory Services LLC22,500$34K0.0%N/A0.134% 9/17/2021Virtu Financial LLC26,373$66K0.0%N/A0.157% 9/3/2021Parametric Portfolio Associates LLC10,554$26K0.0%-59.2%0.063% 8/16/2021Occudo Quantitative Strategies LP14,398$36K0.0%N/A0.086% 8/13/2021Renaissance Technologies LLC78,314$197K0.0%N/A0.468% 8/13/2021Northern Trust Corp13,767$35K0.0%-82.1%0.082% 8/13/2021Geode Capital Management LLC79,556$199K0.0%-40.0%0.475% 8/13/2021Vanguard Group Inc.449,982$1.13M0.0%-35.5%2.687% 8/12/2021XTX Topco Ltd10,864$27K0.0%N/A0.065% 8/12/2021Advisory Services Network LLC35,121$88K0.0%N/A0.210% 8/12/2021Ergoteles LLC30,400$76K0.0%N/A0.182% (Data available from 1/1/2016 forward) ATXI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ATXI shares? During the previous two years, the following institutional investors and hedge funds held shares of Avenue Therapeutics shares: Armistice Capital LLC ($262K), and Boothbay Fund Management LLC ($82K), Moss Adams Wealth Advisors LLC ($27K).Learn more on Avenue Therapeutics' institutional investors. What percentage of Avenue Therapeutics' stock is owned by institutional investors? 17.34% of Avenue Therapeutics' stock is owned by institutional investors. Learn more on ATXI's institutional investor holdings. Which institutional investors have been buying Avenue Therapeutics' stock? The following institutional investors have purchased Avenue Therapeutics' stock in the last 24 months: Armistice Capital LLC ($75K), Boothbay Fund Management LLC ($41.09K), and Moss Adams Wealth Advisors LLC ($11K). How much institutional buying is happening at Avenue Therapeutics? Institutional investors have bought a total of 52,089 shares in the last 24 months. This purchase volume represents approximately $109.57K in transactions. Related Companies Cyclerion Therapeutics Major Shareholders Matinas Biopharma Major Shareholders IM Cannabis Major Shareholders ESSA Pharma Major Shareholders Biofrontera Major Shareholders Dogwood Therapeutics Major Shareholders Addex Therapeutics Major Shareholders Genprex Major Shareholders IN8bio Major Shareholders Ernexa Therapeutics Major Shareholders This page (NASDAQ:ATXI) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.